The global bacillus Calmette-Guérin (BCG) shortage has prompted the use of alternative treatment strategies for patients with intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC).
The global bacillus Calmette-Guérin (BCG) shortage has prompted the use of alternative treatment strategies for patients with intermediate- and high-risk non-muscle invasive bladder cancer (NMIBC).